Mustang Bio Inc., a clinical-stage biopharmaceutical company, appointed Martina Sersch as its chief medical officer.

Before joining Mustang, Sersch was an executive director at Amgen Inc.

New York-based Mustang Bio engages in acquiring, developing and commercializing novel cancer immunotherapy products based on the chimeric antigen receptor engineered T, or CAR T, cell technology.